XNAS · Biotechnology
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$531.52-0.54%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
62/100
Positive
Score components
TickerWhale View
Madrigal Pharmaceuticals scores 62 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Risk its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
- Risk
Quality & growth
30%73Strong
- Revenue growth 149.0%
- EPS growth n/a
Valuation
25%61Positive
- P/E -47.7
- EV/Sales 12.1
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#45 / 139sector rank by TickerWhale Score
TickerWhale Score 62 vs sector average 55.1 (+6.9)
Revenue growth (industry)Top 13%
Return on equity (industry)Top 77%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
69/100Positive vs universe
Ranks 69th of 100 covered names on our technical composite — the composite itself scores 57/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
1 buy · 3 sell · 4 neutral of 8 votes
TickerWhale rates MDGL's technical setup strong — 69th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
4 / 9constructive
- vs 200-day+3.5%
- vs 50-day+0.4%
Momentum
Mixed
- RSI (14)50 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength7· weak trend
- MACD (12,26,9)sell(histogram -1.202)
How the classic verdict is reached
Moving averages (9) agree on buy — 4 buy vs 1 sell — and carry one vote between them.
Oscillators (7) vote individually: 0 buy · 3 sell · 4 neutral.
Result — 1 buy vs 3 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-47.7 · TTM loss
- P/S (TTM)12.1
- P/B29.6
- EV/EBITDA—
- EV/Sales12.1
- PEG—
Profitability & returns
- Gross margin—
- Net margin-25.3%
- ROE-60.9%
- Debt/Equity0.65
Growth
- Revenue growth (YoY)149.0%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $15.5B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGLCurrentMadrigal Pharmaceuticals | 62 | 57 | -47.7 | — | 29.6 | 12.1 | $531.52 | -0.54% | +149.0% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.